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Abstract
Cyxlo-oxygenase (COX)-2 inhibitors, including traditional nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with
increased cardiovascular side effects, including myocardial infarction. We and others have shown that COX-1 and not COX-2
drives vascular prostacyclin in the healthy cardiovascular system, re-opening the question of how COX-2 might regulate
cardiovascular health. In diseased, atherosclerotic vessels, the relative contribution of COX-2 to prostacyclin formation is not
clear. Here we have used apoE2/2/COX-22/2 mice to show that, whilst COX-2 profoundly limits atherosclerosis, this
protection is independent of local prostacyclin release. These data further illustrate the need to look for new explanations,
targets and pathways to define the COX/NSAID/cardiovascular risk axis. Gene expression profiles in tissues from apoE2/2/
COX-22/2 mice showed increased lymphocyte pathways that were validated by showing increased T-lymphocytes in
plaques and elevated plasma Th1-type cytokines. In addition, we identified a novel target gene, rgl1, whose expression was
strongly reduced by COX-2 deletion across all examined tissues. This study is the first to demonstrate that COX-2 protects
vessels against atherosclerotic lesions independently of local vascular prostacyclin and uses systems biology approaches to
identify new mechanisms relevant to development of next generation NSAIDs.
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Introduction
Cyclo-oxygenase (COX) is expressed in two isoforms: constitu-
tive COX-1 and ‘inducible’ COX-2 [1]. COX-1 is associated with
homeostatic processes including protection of the gastro-intestinal
tract and thrombosis. COX-2 is induced by cytokines and
mitogens, and contributes to inflammation, pain, angiogenesis
and cancer. As such, COX-2 is the therapeutic target for non-
steroidal anti-inflammatory drugs (NSAIDs) including diclofenac
(Voltaren), and COX-2 selective NSAIDs including celecoxib
(Celebrex) and rofecoxib (Vioxx). Drug development in this area,
including study of the potentially promising chemopreventative
benefits of COX-2 inhibitors in cancer, was dramatically halted in
2005 with the world-wide withdrawal of rofecoxib and the
continued controversy surrounding the cardiovascular safety issues
of these drugs.
In line with the protective roles of COX isoforms in the gut,
traditional NSAIDs, which inhibit both isoforms of COX, are
associated with serious and potentially fatal gastro-intestinal side
effects [2,3]. We now know that gastro-intestinal side effects are a
result of the combined inhibition of COX-1 and COX-2 in the
gastric mucosa [4] and, as such, highly selective COX-2 NSAIDs,
such as rofecoxib spare the gut [5]. Despite this proven advantage,
rofecoxib was voluntarily withdrawn by its manufacturers when
results of a placebo controlled clinical trial (the APPROVe study)
suggested an increased risk of atherothrombotic events [6]. We
now know that, in general, all drugs that inhibit COX-2, including
traditional NSAIDs, which also inhibit COX-1, are associated
with increased risk of cardiovascular events. This particularly
manifests as an increase in rates of myocardial infarction
[1,7,8,9,10], which is consistent with data from animal models
showing that COX-2 deletion or inhibition can produce a pro-
thrombotic phenotype [11,12,13]. Similarly, some studies show a
pro-atherogenic phenotype of COX-2 inhibition [14,15] or
deletion [13,16], although other pharmacological studies have
suggested no change [17,18,19,20] or reduced atherosclerosis [21]
with pharmacological blockage of COX-2. Taken together, we
have no unifying explanation for the association between COX-2
inhibitor use and cardiovascular events in man.
Inhibition of urinary prostacyclin metabolites by drugs such as
rofecoxib [22] and celecxoib [22] has been used as the main
evidence to support the idea that COX-2 drives prostacyclin
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locally within the vessel wall [8,23]. Accordingly, inhibition of
COX-2 derived prostacyclin release by NSAIDs has been
suggested to remove a local protective block on platelet reactivity,
vascular inflammation and atherosclerosis [8]. However, our
group [24,25], and others [26,27,28], have demonstrated that it is
COX-1 and not COX-2 that drives vascular prostacyclin
production in a healthy cardiovascular system and that urinary
metabolites do not reflect levels in the circulation [24,29]. We have
gone on to use an unbiased systems analysis of COX-2 gene
expression and found that, whilst COX-2 is not in large vessels, it
is expressed in discrete hot spots including within the thymus,
kidney and brain [30]; all locations previously shown to be sites of
COX-2 activity. These findings leave us with no clear explanation
of how COX-2 inhibitors might influence cardiovascular health
[24], especially in those without overt cardiovascular disease such
as those participating in the APPROVe study [6] or in healthy
mice [11].
Data from animal models and human tissue demonstrate that
COX-2 can be induced by inflammation in atherosclerotic vessels
[18,31,32,33,34]. In these conditions, therefore, COX-2 may
provide an additional pathway for local production of protective
prostacyclin. Atherosclerotic disease is likely to be prevalent in
NSAID target populations, such as arthritis patients, and
subclinical atherosclerosis is present in even apparently healthy
individuals. As such, it is essential that the role of COX-2 in
prostanoid generation in atherosclerotic vessels be understood in
order for us to move the field of COX-2 biology and NSAID
development forward. Previous studies have provided mixed
results as to how total prostacyclin formation is altered in animal
models of atherosclerosis [35,36,37] but to our knowledge only
one has addressed the role of particular COX isoforms in this
process. Using a cholesterol-fed rabbit model, Wong et al. [38]
demonstrated aortic prostacyclin and PGE2 formation to be
unaltered by selective COX-2 inhibitors, but partially inhibited by
a non-selective COX-1/COX-2 inhibitor. Although this was a
model of mild fatty streak formation with only modest COX-2
induction and data using pharmacological tools must be
interpreted cautiously, these results suggest that COX-1 remains
the dominant isoform for prostacyclin generation in mildly
atherosclerotic vessels. By contrast, recently published data from
Tang et al. [39] show endothelial-specific deletion of COX-2
exacerbates atherosclerosis in an LDL receptor knockout model,
suggesting a protective role for vascular COX-2-derived prosta-
cyclin.
Here we have used a fat-fed apoE2/2 mouse model to
investigate the effect of genetic deletion of COX-2 on local
prostacyclin release in profoundly atherosclerotic vessels. We have
gone on to establish the extent to which global COX-2 protects
against atherosclerosis and used microarray and pathway analysis
techniques to identify COX-2 regulated gene networks, which
may provide new targets for understanding how COX-2 regulates
cardiovascular health. Whilst these experiments do not yet deliver
definitive answers, this study is the first to demonstrate that COX-
2 protects the cardiovascular system independently of vascular
prostacyclin and shows that systems biology approaches are valid
in this area for the identification of new targets for NSAID-
induced cardiovascular risk. This will, in turn, allow for the
development of safe, efficacious, next generation NSAIDs.
Methods
Animals and induction of atherosclerosis
ApoE2/2/COX-22/2 double knockout mice were generated
by cross of COX-22/2 mice [40] with apoE2/2 mice (C57Bl/6J
background; Charles River, UK) for 2 generations to produce
apoE2/2/COX-2+/2 mice, which were then inter-crossed. The
resulting apoE2/2/COX-22/2 progeny were identified by
genomic PCR, with apoE2/2/COX-2+/+ littermates serving as
controls. To accelerate atherosclerosis in these animals, 12 week
old male and female apoE2/2/COX-22/2 and apoE2/2/COX-
2+/+ animals were fed a high fat, high cholesterol diet (21% fat,
1.25% cholesterol, cholate-free; D12108; Research Diets, USA)
for 10 weeks. The reported effects of COX-2 deletion on
atherosclerosis and vascular prostanoid release were apparent in
both male and female mice.
At the termination of all studies, animals were killed by CO2
narcosis, and the vasculature immediately perfused with phosphate
buffered saline (PBS) across the heart. For some studies, mice were
additional perfused with 10% neutral buffered formalin at
physiological pressure.
This study was carried out in strict accordance with the
guidelines set out under Animals (Scientific Procedures) Act 1986.
All procedures have been approved by Imperial College Ethical
Review Panel and under a designated Home Office License (PPL
70/7013) and were carried out by Home Office approved
personnel. All efforts were made to minimise suffering.
Optical projection tomography
Perfusion fixed aortic arches from apoE2/2/COX-2+/+ and
apoE2/2/COX-22/2 mice were cleaned of peri-adventitial
material and embedded in agarose (Invitrogen, UK) before
dehydration in methanol and optical clearing in 66% benzyl
alcohol, 34% benzyl benzoate (Acros Organics, UK). Tissue
morphology and plaque distribution was recorded by optical
projection tomographic imaging of auto-fluorescent emission
(405–445 nm excitation) using a Bioptonics 3001 tomograph as
previously described [41]. Briefly, 400 projection images were
recorded at 0.9u increments of rotation, and the three-dimensional
volume reconstructed by Hamming-filtered back-projection (NRe-
con; Skyscan, Belgium). Plaque volume was quantified using CTan
software (Skyscan, Belgium) by a blinded observer.
Histological analysis and immunohistochemistry
Brachiocephalic arteries were collected from perfusion fixed
apoE2/2/COX-2+/+ and apoE2/2/COX-22/2 mice and post-
fixed in 10% neutral buffered formalin (Sigma, UK) for 48 hrs,
before dehydration and processing to paraffin wax. 5 mm thick
serial sections were cut perpendicular to the vessel axis, and
stained using Verhoeff’s van Gieson method (Elastic Stain Kit;
Sigma, UK). From each vessel, three representative sections were
selected with at least 200 mm spacing. From photomicrographs of
these, planimetric measurements of lesion size (defined as the area
delineated by the luminal border and internal elastic lamina) were
recorded using Photoshop CS5 Extended software (Abobe Systems
Inc, USA). Lesion lipid content was estimated by measuring de-
lipidated intra-plaque voids, as previously described [42].
Immunohistochemistry for a-smooth muscle actin (aSMA),
Mac2, B220 and CD3 was performed according to the labeled
streptavidin-biotin method using rehydrated paraffin sections.
Before staining for B220, heat induced epitope retrieval was
performed using pH 10 Tris-HCl antigen retrieval solution
(Sigma, UK). For all stains, non-specific binding was blocked with
10% normal goat serum (Vector Labs, UK), 2.5% bovine serum
albumin (Sigma, UK) and 2.5% non-fat milk powder (Marvel,
UK) in PBS (Sigma, UK) Unconjugated primary antibodies were
applied and incubated as indicated- anti-aSMA (Sigma, UK): 1/
400 dilution; 30 min incubation; anti-Mac2 (Cederlane Labs,
USA): 1/6000 dilution, overnight incubation; anti-B220 (Biole-
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gend, UK): 1/200 dilution, overnight incubation; anti-CD3 (AbD
Serotec, UK): 1/200 dilution, overnight incubation. Biotinylated
goat anti-mouse IgG (aSMA) or goat anti-rat IgG secondary
antibodies (Mac2, B220, CD3) were applied at 1/400 dilution for
30 mins, followed by streptavidin-conjugated horseradish perox-
idase (Extravidin-Peroxidase; Sigma, UK; 1/400 dilution; 30
mins). Immunoperoxidase complexes were visualised by the
application of 3,3-diaminobenzidine (Vector Labs, UK) and its
development into an insoluble product. Specificity of staining was
confirmed using appropriate positive and negative control tissues,
and by substituting the primary antibody for an isotype matched
irrelavent antibody. aSMA and Mac2 immunoreactivity, were
quantified by colour deconvolution (Photoshop CS5 Extended,
Abode Systems, USA) and the immunoreactive area expressed as a
fraction of the total lesion area. B220 and CD3 were quantified by
manual count by a blinded observer of immunoreactive cells in
each of lesion, media and adventitia. Counts were expressed
according to the total area of the appropriate vessel wall layer,
measured as above.
Sudan IV lipid staining
The aortic tree, including its major branches, was dissected
from apoE2/2/COX-2+/+ and apoE2/2/COX-22/2 mice per-
fused with PBS. Vessels were cut open to reveal their luminal
surface, and pinned en face onto Sylgard coated plates (Dow
Corning, USA). After brief fixation (10 mins; 10% neutral buffered
formalin; Sigma, UK), vessels were rinsed in 70% ethanol before
incubation (20 mins, room temperature) with filtered sudan IV
solution (0.5% in 50% ethanol, 50% acetone; Sigma, UK). The
stain was differentiated in 80% ethanol (5 mins), and vessels rinsed
in running water. Aortas were photographed and the sudan IV-
stained area quantified by image analysis (Photoshop CS5
Extended; Adobe Systems, USA) by a blinded observer.
En face confocal imaging of the aortic arch
Perfusion fixed aortic arches were carefully dissected of peri-
adventitial material and 2 mm rings of the proximal (between
aortic root and base of the brachiocephalic artery) and mid-arch
(between the base of the brachiocephalic artery and left carotid
artery) removed for immunostaining. Briefly, aortic arch rings
were treated with 0.1% Triton X-100 (Sigma, UK) and 20%
normal goat serum (Vector Labs, UK; 12 hrs, room temperature)
to permeabilize membranes and block non-specific binding, then
incubated with primary antibodies raised against COX-1 (1:50;
4 hrs, room temperature; Cayman Chemical, USA) or COX-2
(1:50; 4 hrs, room temperature; Cayman Chemical, USA). Aortic
rings were then treated with AlexaFluor-594-conjugated goat anti-
rabbit IgG secondary antibodies (Invitrogen, UK) before incuba-
tion with Alexa-Fluor-488-conjugated anti-CD31 (1:100; 12 hrs,
4uC; Biolegend, UK) and DAPI (25 mg/ml; 5min room temper-
ature; Invitrogen, UK) to label endothelial cells and cell nuclei,
respectively. Tissues were washed thoroughly with PBS between
incubations. After staining, aortic rings were cut open to reveal the
luminal surface, mounted flat between a glass slide and coverslip
with aqueous hard-set media (Vector Labs, UK) and pressed until
the media had firmly set.
The luminal surface of the arch was visualized with a Leica SP5
inverted confocal microscope at 40X objective magnification.
Laser and gain settings were fixed at the beginning of each
imaging protocol. Areas corresponding to lesser and greater
curvature of the aortic arch were determined by tissue orientation
and confirmed by the cell morphology in the CD31+ endothelial
cell layer. In these regions, Z-stacks were recorded which included
the endothelial cell, intra-plaque and medial layers. These layers
were identified based cell and nuclear morphology and orienta-
tion, and CD31 immunoreactivity. Images presented and analysed
represent a single plane from each Z-stack which best corresponds
to the layer of vessel under study (i.e. endothelial layer, intraplaque
layer or medial layer). Due to the uneven morphology of the
atherosclerotic vessel, in some cases individual Z-stack planes may
have cut across more than one vessel layer. COX-1 and COX-2
was quantified as mean fluorescence intensity using ImageJ
software (National Institutes of Health, USA).
Aortic COX activity bioassays
Aortic arch, brachiocephalic artery and thoracic aorta (regions
both with and without grossly visible plaque formation) were
isolated from animals perfused with PBS. Vessels were carefully
dissected into 2 mm rings and placed immediately into individual
wells of a 96 well microtitre plate containing DMEM (Sigma, UK)
containing Ca2+ ionophore A23187 (50 mM; Sigma, UK). Vessels
were incubated at 37uC for 30 mins then conditioned media was
removed and subsequently analysed by competitive immunoassay
for 6-keto-PGF1a (a stable breakdown product of prostacyclin;
Cayman Chemical, USA) and PGE2 (Cisbio, France).
qPCR
Tissues (heart, lung, liver, spleen, thymus, kidney) were removed
from fat-fed apoE2/2 COX-2+/+ and apoE2/2 COX-22/2 mice
and snap frozen, homogenised, and total RNA extracted using a
silica column-based kit (Nucleospin RNA II; Machery-Nagal,
UK). RNA was converted to cDNA by reverse transcriptase
(Superscript II; Invitrogen, UK) with oligo(dT) primers (Invitro-
gen, UK) and qPCR performed using a Rotor-Gene Q instrument
(Qiagen, UK). Ptgs2 (probe ID: Mm00477214_m1), ptgs2 (probe
ID: Mm00478374_m1) and rgl1 (probe ID: Mm00444088_m1)
gene expression levels were determined using TaqMan expression
assays and quantified relative to levels of 18S rRNA (probe ID:
Mm03928990_g1) using the comparative Ct method.
Microarray analysis
Total RNA extracted from apoE2/2/COX-2+/+ and apoE2/
2/COX-22/2 mouse lung, liver and thymus homogenates as
above were subject to standard microarray procedures. Samples
were converted to cDNA, fragmented, labelled, and hybridized to
Illumina MouseRef-8v3 BeadChip arrays (Illumina, UK). Quality
control and basic interpretation of data was performed at Bart’s
and The London Genome Centre, Queen Mary, University of
London before datasets were received for further analysis. Data
were subsequently analysed for differential expression levels and
gene pathways using the Ingenuity iReport service (Ingenuity
Systems, USA) and statistical significance determined using the
linear models for microarray data (LIMMA) modified t-test
method. Full methodological details can be found at http://
www.ingenuity.com/getireport/pdf/
ingenuity_robust_unattended_microarray_analysis.
Blood cell and cytokine analyses
Venous blood was collected from the inferior vena cava. Plasma
was separated from heparinized blood (10 U/ml; Leo Laborato-
ries, UK) and levels of IL-1b, IL-2, IL-4, IL-10, IL-12 (total),
IFNc, KC and TNFa were measured using a multiplex
immunoassay system (Meso Scale Diagnostics, USA). Plasma
cholesterol and triglyceride levels and whole blood leucocyte
counts were determined by a commercial veterinary diagnostics
service (IDEXX Laboratories, UK).
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Statistics and data analysis
Data were analysed using Prism 5.0 software (Graph pad
Software, USA) and are presented as mean6SEM. Data were
compared by Student’s unpaired t-test unless otherwise stated. ‘n’
refers to the number animals from which observations were made;
where multiple measures were obtained from the same animal,
values were averaged and considered as n = 1. Differences were
considered significant if p,0.05.
Results and Discussion
Effect of COX-2 deletion on atherosclerosis in mice
In man, NSAIDs, including COX-2 selective inhibitors, are
associated with increased atherothrombotic events [10]. This
suggests that COX-2 may protect the cardiovascular system
against atherosclerosis. Experimental results in this area are not
entirely united with increases [14,15], decreases [21] and no
change [17,18,19,20] in atherosclerosis being reported in previous
studies of pharmacological COX-2 inhibition. This possibly
reflects differences in timing, model and the degree/selectivity of
COX-2 inhibition achieved since any concurrent COX-1 inhibi-
tion is likely to be dominated by effects on platelet thromboxane
and thereby protective against atherosclerotic lesion formation
[18]. Importantly, in mice, both pre- [16] and post-natal [13]
global COX-2 gene deletion is associated with increased
atherosclerosis. In agreement, here we show that apoE2/2 mice
developed severe atherosclerosis when fed a high fat, high
cholesterol diet (Figure 1) and that this was exacerbated by
deletion of COX-2. Atherosclerotic plaque burden (Figure 1a,b)
and vascular lipid accumulation (Figure 1d) were all increased in
apoE2/2/COX-22/2 mice compared to littermate apoE2/2/
COX-2+/+ control animals. This augmented atherosclerosis was
associated with increased vascular inflammation, as indicated by
an increase in accumulation of Mac2+macrophage-like cells in the
plaques, without alteration in plaque lipid or smooth muscle
content (Figure S1). We also observed increased plasma cholesterol
levels in apoE2/2/COX-22/2 mice (Figure 1c) possibly reflecting
previously described changes in lipoprotein function [16] and
leucocyte-lipoprotein exchange pathways [43]. These increases in
total plasma cholesterol alone however may not account for
increased atherosclerotic burden since previous studies in this
model show similar and greater increases in circulating cholesterol
without increased plaque formation [44,45].
Role of COX-2 enzyme activity on prostacyclin
production by atherosclerotic vessels
It is generally accepted that the inflammation associated with
atherosclerosis leads to the induction of COX-2 [18,31,32,33,34].
However, COX-1 remains detectable in atherosclerotic tissue and
the relative contribution of COX-2 to prostacyclin production in
atherosclerotic vessels remains unclear [38] [39]. This is clearly a
critical question since the prevailing dogma dictates that, in
patients who are likely to have pre-existing atherosclerosis, COX-2
drives local vascular prostacyclin production [13], an idea that has
been adopted by the American Heart Association and has
influenced prescribing advice [46]. We found evidence of some
COX-2-like immunoreactivity in atherosclerotic vessels alongside
abundant COX-1-like imunoreacitivty (Figure 2). This COX-2
staining was specific since it was lost in COX-2-deficient mouse
vessels (Figure S2). Sequential (Z) scanning through vessels
suggested COX-2-like immnuoreactivity was most abundant in
the endothelial and intraplaque layers and somewhat less present
in the media (Figure 2; Figure S2), although the heterogeneous
composition and uneven morphology of the diseased vessels
complicates precise localisation. Further, immunohistochemical
analysis does not allow quantitative comparison of different
protein levels, and protein levels, in turn, may poorly reflect
bioactivity. Consequently, in this study we have systematically
assessed the ability of isolated atherosclerotic vessels from apoE2/
2 mice to release prostacyclin (measured as its stable breakdown
product, 6-keto-PGF1a) and PGE2, and how this is altered by
deletion of the COX-2 gene. In order to ensure that COX
expression rather than the level of phospholipase A2 activation was
the rate-limiting step in prostaglandin production we measured
release after stimulation with Ca2+ ionophore A23187. Our
analysis determined the role of COX-2 in prostacyclin release
from segments of the brachiocephalic artery (Figure 2a), aortic
arch (Figure 2b) and thoracic aorta, which were each heavily
burdened with atherosclerosis (Figure 2c), as well as plaque-free
areas of the thoracic aorta (Figure 2d).
Previous studies have provided mixed results as to how total
prostacyclin formation is altered in animal models of atheroscle-
rosis [35,36,37]. Here we observed similar levels of prostacyclin
release between vessels burdened with atherosclerosis and those
free of disease by gross examination (Figure 2c,d). Moreover,
regardless of the level of atherosclerosis, COX-2 did not detectably
contribute to prostacyclin production by these isolated vessels
(Figure 2). Similar results were seen when PGE2 release by the
same vessels was measured (Figure 2). The physical trauma of
removal of the vessel from the animal, ex vivo assay conditions and
A23187 stimulation result in maximum activation of the vessel,
conditions which may not reflect those in vivo and which may
confound interpretation of these results. In order to address this we
also measured plasma levels of 6-keto-PGF1a, a marker we have
previously found to reflect systemic vascular prostacyclin produc-
tion [24]. 6-keto-PGF1a was readily detectable in plasma and the
levels did not differ between apoE2/2/COX-2+/+ (4196106 pg/
ml) and apoE2/2/COX-22/2 mice (436666 pg/ml; p = 0.90).
These findings are consistent with previous reports from hyper-
lipidemic rabbits [38] and our previous observations in healthy
mouse vessels where COX-2 deletion did not alter vascular
prostacyclin release, unless vessels are treated with inflammatory
or mitogenic stimuli to induce COX-2 [24] or plasma prostacyclin
unless animals were treated with high dose of LPS [47]. Whereas
COX-1 deletion removed prostacyclin release in vitro and in vivo by
.90% [24,30]. Taken together, our data demonstrate that, despite
modest enzyme induction, COX-2 does not meaningfully drive
local vascular prostacyclin production in diseased plaque bur-
dened atherosclerotic vessels or, as in healthy animals [24,30]
contribute to global circulatory prostacyclin release in animals
with atherosclerosis.
Figure 1. COX-2 deletion augments atherosclerosis in apoE2/2mice. Optical projection tomographic imaging of the aortic arch from fat-fed
apoE2/2/COX-2+/+ and apoE2/2/COX-22/2 mice (a) demonstrated a clear increase in atherosclerotic lesion burden in the lesser curvature of the arch,
and its major branches: the brachiocephalic (BCA), left carotid and left subclavian arteries. Planimetric measurement of plaque area in van Gieson-
stained histological sections of the brachiocephalic artery confirmed these observations (b), showing increased plaque area in apoE2/2/COX-22/2
mice. Similarly, plasma cholesterol levels (c) and aortic lipid accumulation measured by en face sudan IV staining (d), were increased in apoE2/2 mice
lacking COX-2. *; p,0.05 vs apoE2/2/COX-2+/+ by unpaired t-test; n = 8-12.
doi:10.1371/journal.pone.0098165.g001
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Figure 2. COX-2 deletion does not alter prostacyclin production by atherosclerotic vessels. Production of Prostacyclin and PGE2 by
isolated rings of brachiocephalic artery (a) and aortic arch (b), and from plaque-bearing (c) and plaque-free regions of thoracic aorta (d) from fat-fed
apoE2/2/COX-2+/+ and apoE2/2/COX-22/2 mice demonstrated little role for COX-2 in the production of either prostaglandin in atherosclerotic
vessels. In agreement, en face confocal immunofluorescence imaging of the lesser curvature of the aortic arch (b) suggests that whilst both COX-1
and COX-2-like immunoreactivity was present in atherosclerotic vessels, the COX-1 isoform was the predominant isoform. Sequential (Z) scanning
through en face vessel preparations suggested COX-2 was more abundant in the endothelial and intraplaque layers than the media. Images are
merges of red (COX1 or COX2), green (CD31 – endothelial cells) and blue (DAPI – cell nuclei) channels. n = 4–6.
doi:10.1371/journal.pone.0098165.g002
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These observations however leave us now with no explanation
of how COX-2 inhibition or gene deletion exacerbates athero-
sclerosis. Thus, with the idea that COX-2 mediates prostacyclin
release in healthy [24] and atherosclerotic vessels (this study)
removed, we must now address the possibility that COX-2 in sites
remote to the affected vessel can protect indirectly. When doing so,
it must be remembered that COX-2 may be expressed not only in
parenchyma, but also in organ specialized microvasculature or
other stromal cells. Indeed, endothelial specific COX-2 has been
shown to protect against atherogenesis [39], despite our findings
that vascular COX-2 has no role for prostacyclin production in
affected vessels. In order to explore these hypotheses, we profiled
COX-1 and COX-2 gene expression in a panel of tissues from
atherosclerotic apoE2/2 mice to find sites where loss of COX-2
may influence pathophysiology. COX-2 message was differentially
expressed across tissues with highest levels present in the thymus,
and lowest in the liver (Figure 3a), results that are consistent with
our recent observations using a COX-2 luciferase mouse revealing
COX-2 gene hot spots in these tissues [30]. COX-1 expression
was more consistent between tissues (Figure 3b) and in agreement
with our previous observations of COX activity in tissues from
healthy animals, was the dominant isoform expressed in all tissues
examined. Interestingly, the thymus, the site of T-lymphocyte
maturation, possessed not only the highest level of COX-2
expression, but also the lowest level of COX-1 expression,
suggesting prostanoid production in this tissue may be relatively
dependent on COX-2 in this model (Figure 3c).
Effect of COX-2 deletion on the transcriptome in
atherosclerotic mice; identification of T-lymphocyte
pathways
To generate new ideas about how COX-2 at distant sites might
regulate atherosclerotic disease in the vessel wall we took a systems
biology approach and measured the transcriptome of tissues from
apoE2/2/COX-2+/+ and apoE2/2/COX-22/2 mice. We exam-
ined the thymus, the highest COX-2 expressing tissue found, the
lung, which is highly vascularised and sensitive to inflammation,
and the liver, the major site of lipid metabolism. We then
performed pathway analysis of microarray data to understand how
changes in gene expression might influence biological processes
(Figure 4, Figures S3-S5). In all three tissues, gene pathways
involved in lymphocyte function and antigen presentation were
amongst those most consistently and significantly altered (Figure 4,
Figures S3-S5). To validate the importance of these pathways, we
measured inflammatory cell counts in blood and found increased
numbers of circulating lymphocytes in atherosclerotic mice lacking
COX-2, but normal levels of monocytes, neutrophils, and
eosinophils (Figure 5a). Similarly, deletion of COX-2 was
associated with an increase in plasma levels of the lymphocyte
cytokines IL-2 and IL-12, as well as the neutrophil chemoat-
tractant, KC (Figure 5b). To determine if these changes extended
to the atherosclerotic vessels themselves we examined T- (CD3+)
and B-lymphocyte (B220+) accumulation in histological sections.
B-lymphocytes were rarely observed in atherosclerotic vessels
(Figure 6a), but T-lymphocytes were present as focal accumula-
tions in the adventitial layer (Figure 6b). Crucially, the number of
T-lymphocytes present was increased in atherosclerotic vessels
from apoE2/2 lacking COX-2 (Figure 6b).
These findings suggest that T-lymphocytes may mediate
enhanced atherosclerosis in COX-2-deficient apoE2/2 mice.
Mature T-lymphocytes themselves, however, do not normally
express COX-2 [48,49,50], and indeed, it has been reported that
T-lymphocyte-specific COX-2-deletion does not alter atheroscle-
rosis in an apoE-deficient model [50]. By contrast, it is known that
deletion or inhibition of COX-2 alters the development of T-
lymphocytes in the thymus [51], a site we have identified as highly
expressing COX-2 in these mice. Further, prostanoids are
reported to regulate a range of T-lymphocyte functions including
proliferation, apoptosis and Th1/Th2 balance [48]. This latter
effect may be particularly relevant to our study because we
observed that deletion of COX-2 produced an increase in pro-
atherogenic Th1-type cytokines (IL-2 and IL-12) and genes
(STAT1, IRF1) but not Th2-type cytokines (IL-4, IL-10). A full
Figure 3. COX gene expression in tissue from atherosclerotic
apoE2/2 mice. COX-2 (ptgs2) (a) and COX-1 (ptgs1) (b) gene
expression levels measured by quantitative RT-PCR in a panel of tissues
from atherosclerotic apoE2/2 mice indicated that COX-1 was expressed
at a similar level and was the dominant isoform across all studied
tissues. COX-2 expression showed more variation across tissues, with
the highest levels present in the thymus, which also had the greatest
COX-2:COX-1 expression ratio of any tissue examined (c). n = 4-6.
doi:10.1371/journal.pone.0098165.g003
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Figure 4. Deletion of COX-2 is associated with up-regulation of lymphocyte-related gene expression patterns, and down-regulation
of rgl1 in tissue from fat-fed apoE2/2 mice. Microarray analysis indicated 82, 87 and 90 differentially expressed genes (DEGs), respectively, in
thymus (a), liver (b) and lung (c) from fat-fed apoE2/2/COX-2+/+ and apoE2/2/COX-22/2mice. Volcano plot summaries of these data sets illustrate the
distribution of effect size and statistical significance. Gene expression differing between genotypes .1.2-fold with p,0.05 highlighted in red, were
considered for pathway analysis. Differential gene expression patterns demonstrated only weak overlap between tissues, but one gene, rgl1, was
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gene validation and interpretation of how the thymus and
associated lymphocyte pathways may be linked to COX-2,
NSAIDs and atherosclerosis is beyond the scope of this study
and remains the subject of investigation. Nevertheless, these ‘proof
of concept’ studies provide a direction by which the cardiopro-
tective properties of COX-2 at sites distant to the vessel may be
identified.
Association between COX-2 and the novel target gene
rgl1 in tissue from atherosclerotic mice
In addition to lymphocyte-related pathways, our microarray
analysis of tissue from apoE2/2 mice indicated that COX-2 was
highly associated with a novel target gene, ral guanine nucleotide
dissociation stimulator-like 1 (rgl1). Indeed, rgl1 was amongst
strongly altered (down-regulated) genes in all three examined
altered (down-regulated) in all tissues studied (d). Rgl1 down-regulation was confirmed in each tissue of apoE2/2/COX-22/2 mice by qPCR (e).
Ingenuity pathway analysis of this data showed that in the thymus (f), liver (g) and lung (h), biological pathways/processes related to T- and/or B-
lymphocyte function were amongst the most consistently altered pathways in each tissue. Tables show the top 15 altered biological pathways/
processes and implicated genes (green: increased expression; red: decreased expression). Statistical testing of microarray data was performed using a
linear model for microarray data modified t-test. n = 4.
doi:10.1371/journal.pone.0098165.g004
Figure 5. COX-2 deletion increases circulating levels of lymphocytes and lymphocyte-related cytokines in fat-fed apoE2/2 mice.
Measurement of plasma levels of cytokines by multiplex immunoassay (a) demonstrated an increased in the lymphocyte-related cytokines IL-2 and IL-
12 (total) and the neutrophil chemoattractant KC, but no change in levels of TNFa, IL-1b, IL-4, IL-10 or IFNc. Cell counts in whole blood (b), measured
in parallel, indicated an increase in circulating lymphocytes, but not monocytes, neutrophils or eosinophils. *; p,0.05 vs apoE2/2/COX-2+/+ by
unpaired t-test; n = 10–25.
doi:10.1371/journal.pone.0098165.g005
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tissues (thymus, lung, liver), and the only common altered gene
between them (Figure 4d; Figures S3-S5). This was confirmed in
each tissue by qPCR (Figure 4e). The mechanism of rgl1 down-
regulation is unclear since it was observed in tissues with both high
(thymus, lung) and low (liver) COX-2 expression. This suggests the
link between rgl1 and COX-2 must be mediated either (a) by a
single COX-2 expressing cell type present in all tissues such as
leucocytes or nerves, or (b) by a circulating factor or other systemic
influence triggered by loss of COX-2 at a distant site.
There is little literature describing the function and regulation of
rgl1 in mammalian systems. Rgl1 is a Ral guanine nucleotide
exchange factor (RalGEF) closely related to RalGDS (Ral guanine
nucleotide dissociation stimulator). RalGEFs are activated by Ras
(and related molecules) and catalyse the activation of small G-
proteins of the Ral family. The Ras/RalGEF/Ral pathway has
been linked to many biological effects (reviewed in [52]) including
proliferation, migration and inflammation (NFkB activation). If
and how down-regulation of rgl1 by COX-2 deletion might
regulate atherogenesis is unclear since reduced Ral signaling might
be expected to reduce inflammation and proliferation. It should also
be noted that Ras/RalGEF/Ral is a key pathway in cancer [52]
and as such our findings may be of equal or greater relevance to
understanding how NSAIDs exert their chemo-preventative
effects. Clearly the mechanism(s) by which COX-2 regulates rgl1
expression and the biological consequences of this warrant further
investigation.
Summary and conclusions
Our previous work showed that COX-1, and not COX-2,
mediates prostacyclin release in healthy vessels, and that urinary
metabolites of prostacyclin do not reflect those in the circulation
[24]. Here, we extend these observations, making the critical
observation that COX-2 protects against atherosclerosis, but that
this protection is mediated at some distant site and independent of
local prostacyclin by the vessel. With the idea that COX-2
mediates vascular prostacyclin release removed, we must now
revisit the question of where COX-2 is expressed and how this
might influence vascular disease at distant sites. In this study we
have performed microarray analysis of gene expression and used a
systems biology approach to identify lymphocyte pathway
signatures. This leads us to propose a role for the thymus and
T-lymphocytes in the increased atherosclerosis observed in mice
lacking COX-2. In addition, we have identified a novel target
gene, rgl1, which is strongly linked to COX-2 in tissue from
atherosclerotic mice.
The importance of this study is to show that in a model where
COX-2 protects against atherosclerosis, this is independent of
prostacyclin at the site of vascular lesions. Our study does not
provide definitive answers but offers important new hypotheses for
investigation and illustrates approaches that will, in the future, lead
to a full understanding of how COX-2 might protect the
cardiovascular system. NSAIDs remain the most common over
the counter medications taken worldwide and there is a clear
Figure 6. COX-2 deletion enhances T-lymphocyte infiltration into the adventitia of atherosclerotic vessels. Atherosclerotic lesions in
the brachiocephalic artery of fat-fed apoE2/2/COX-2+/+ and apoE2/2/COX-22/2 mice were examined for B- and T-lymphocytes respectively by
immunohistochemistry for B220 (a) and CD3 (b). B220+ cells were rarely observed in vessels of either genotype. By contrast, CD3+ cells were present
as focal accumulations in the adventitial layer of apoE2/2 mice, and the number and density of CD3+ cells present here was increased by deletion of
COX-2. *; p,0.05 vs apoE2/2/COX-2+/+ by unpaired t-test; n = 5–10.
doi:10.1371/journal.pone.0098165.g006
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requirement for the continued development of new drugs in this
class. These should spare the cardiovascular system as well as the
gut, to fulfill their potential as anti-inflammatory drugs as well as in
new clinical indications such as cancer.
Supporting Information
Figure S1 COX-2 deletion increases plaque macro-
phage but not lipid and smooth muscle content.
Atherosclerotic lesions in the brachiocephalic artery of fat-fed
apoE2/2/COX-2+/+ and apoE2/2/COX-22/2 mice were
examined for estimated lipid content, smooth muscle/ myofibro-
blast content and macrophage content respectively by measuring
intra-plaque voids in elastic Van Gieson (EVG) stained histological
sections (a), or by immunohistochemistry for a-smooth muscle
actin (aSMA; b) and Mac2 (c). Intra-plaque voids reminiscent of
extracellular cholesterol crystals and Mac2 immunoreactivity were
abundant in the intimal layer of all student vessels but rarer in the
medial and adventital layers, whereas aSMA was present in both
the intimal and medial layers. The relative abundance of lipid-like
voids and aSMA immunoreactivity was not altered by COX-2
deletion. By contrast, vessels from apoE2/2 mice lacking COX-2
exhibited significantly more Mac2 immunoreactivity than vessels
from control mice. *; p,0.05 vs apoE2/2/COX-2+/+ by unpaired
t-test; n = 8–10.
(PDF)
Figure S2 COX-2 is expressed in the atherosclerotic
vessel and absent in COX-22/2 tissue. Atherosclerotic
vessels from the lesser curvature of the aortic arch exhibited some
COX-2-like immunoreactivity when examined by en face confocal
immunofluorescence imaging. Sequential (Z) scanning through the
vessel suggested this was present primarily in the endothelial and
intraplaque layers with less present in the medial layers. In each
case this was lost in COX-2-deficient mice demonstrating the
antibody specificity. *; p,0.05 by two-way ANOVA. n= 4–6.
(PDF)
Figure S3 Effect of COX-2 deletion on the transcrip-
tome of the thymus in apoE2/2 mice. Whole thymus from
fat-fed apoE2/2/COX-2+/+ and apoE2/2/COX-22/2 mice was
examined for differential gene expression by microarray analysis.
Genes exhibiting .1.25-fold expression level between genotypes
are displayed. Data was analysed by the linear models for
microarray analysis method. n= 4.
(PDF)
Figure S4 Effect of COX-2 deletion on the transcrip-
tome of the lung in apoE2/2 mice. Whole lung from fat-fed
apoE2/2/COX-2+/+ and apoE2/2/COX-22/2 mice was exam-
ined for differential gene expression by microarray analysis. Genes
exhibiting .1.25-fold expression level between genotypes are
displayed. Data was analysed by the linear models for microarray
analysis method. n = 4.
(PDF)
Figure S5 Effect of COX-2 deletion on the transcrip-
tome of the liver in apoE2/2 mice. Whole liver from fat-fed
apoE2/2/COX-2+/+ and apoE2/2/COX-22/2 mice was exam-
ined for differential gene expression by microarray analysis. Genes
exhibiting .1.25-fold expression level between genotypes are
displayed. Data was analysed by the linear models for microarray
analysis method. n = 4.
(PDF)
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